Comparative Pharmacology
Head-to-head clinical analysis: PIPERAZINE CITRATE versus PRAZIQUANTEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERAZINE CITRATE versus PRAZIQUANTEL.
PIPERAZINE CITRATE vs PRAZIQUANTEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
Praziquantel increases the permeability of schistosome cell membranes to calcium ions, causing severe contraction and paralysis of the worm musculature, leading to dislodgment and death.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
20 mg/kg orally three times daily for 1 day for schistosomiasis; 25 mg/kg orally three times daily for 1 day for clonorchiasis and opisthorchiasis; 5-10 mg/kg orally single dose for taeniasis; 15-25 mg/kg orally single dose for hymenolepiasis; 25 mg/kg orally three times daily for 1 day for paragonimiasis, fasciolopsiasis, and heterophyiasis.
None Documented
None Documented
Clinical Note
moderatePraziquantel + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Praziquantel."
Clinical Note
moderatePraziquantel + Cyclosporine
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 1-1.5 hours for praziquantel; 4-6 hours for its main metabolite (4-hydroxypraziquantel). Half-life prolonged in patients with severe hepatic impairment.
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Primarily renal: approximately 80% of metabolites excreted in urine (unchanged drug <0.1%); fecal excretion accounts for about 15%.
Category C
Category A/B
Anthelmintic
Anthelmintic
"The metabolism of Cyclosporine can be decreased when combined with Praziquantel."